INFORMASILENGKAP.COM

Receptor lizofosfatidne kiseline 3
Receptor lizofosfatidne kiseline 3
Identifikatori
Simboli	LPAR3; EDG7; Edg-7; HOFNH30; LP-A3; LPA3; RP4-678I3
Vanjski ID	OMIM: 605106 MGI: 1929469 HomoloGene: 8123 IUPHAR: LPA3 GeneCards: LPAR3 Gene
Ontologija gena
Molekularna funkcija	• vezivanje G-protein alfa podjedinice; • aktivnost G-protein spregnutog receptora; • proteinsko vezivanje; • fosfolipidno vezivanje;
Celularna komponenta	• citoplazma; • ćelijska membrana; • integralno sa ćelijskom membranom; • ćelijska površina;
Biološki proces	• activacija MAPK aktivnosti; • signalni put G-protein spregnutog receptora; • aktivacija fosfolipaze C; • povišenje koncentracije citozolnih jona kalcijuma;
Pregled RNK izražavanja
	podaci
Ortolozi
Vrsta	Čovek
Entrez	23566
Ensembl	ENSG00000171517
UniProt	Q9UBY5
RefSeq (mRNA)	NM_012152.2
RefSeq (protein)	NP_036284.1
Lokacija (UCSC)	Chr 1:; 85.28 - 85.36 Mb
PubMed pretraga	[1]

Receptor lizofosfatidne kiseline 3 (LPA₃) je protein koji je kod ljudi kodiran LPAR3 genom.^[1]^[2] LPA₃ je G protein spregnuti receptor za koji se vezuje lipidni signalni molekul lizofosfatidna kiselina (LPA).^[3]

Funkcija

Ovaj protein je član familije I G protein spregnutih receptora, kao i EDG familije. On funkcioniše kao ćelijski receptor za lizofosfatidnu kiselinu i podstiče mobilizaciju kalcijuma. Ovaj receptor se predominantno spreže sa G(q/11) alfa proteinima.^[1]

Reference

^ ^а ^б „Entrez Gene: LPAR3 Lysophosphatidic acid receptor 3”.
^ Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K (1999). „Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid”. J. Biol. Chem.. 274 (39): 27776—85. PMID 10488122. doi:10.1074/jbc.274.39.27776.
^ Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J (2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology. 50 (1): 157—186. PMID 20055701. doi:10.1146/annurev.pharmtox.010909.105753.

Literatura

Contos JJ, Ishii I, Chun J (2001). „Lysophosphatidic acid receptors.”. Mol. Pharmacol.. 58 (6): 1188—96. PMID 11093753.
Im, D. S.; Heise, C. E.; Harding, M. A.; et al. (2000). „Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate.”. Mol. Pharmacol.. 57 (4): 753—9. PMID 10727522.
Fitzgerald, L. R.; Dytko, G. M.; Sarau, H. M.; et al. (2000). „Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid.”. Biochem. Biophys. Res. Commun.. 273 (3): 805—10. PMID 10891327. doi:10.1006/bbrc.2000.2943.
Tokumura, A.; J, Sinomiya; Kishimoto, S.; et al. (2002). „Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.”. Biochem. J.. 365 (Pt 3): 617—28. PMC 1222725 . PMID 11982483. doi:10.1042/BJ20020348.
Hama, K.; K, Bandoh; Kakehi, Y.; et al. (2002). „Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.”. FEBS Lett.. 523 (1-3): 187—92. PMID 12123830. doi:10.1016/S0014-5793(02)02976-9.
Strausberg, R. L.; Feingold, E. A.; Grouse, L. H.; et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A.. 99 (26): 16899—903. PMC 139241 . PMID 12477932. doi:10.1073/pnas.242603899.
Cremers, B.; M, Flesch; Kostenis, E.; et al. (2003). „Modulation of myocardial contractility by lysophosphatidic acid (LPA).”. J. Mol. Cell. Cardiol.. 35 (1): 71—80. PMID 12623301. doi:10.1016/S0022-2828(02)00279-1.
Fujita, T.; S, Miyamoto; Onoyama, I.; et al. (2003). „Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.”. Cancer Lett.. 192 (2): 161—9. PMID 12668280. doi:10.1016/S0304-3835(02)00713-9.
Jin Y, Knudsen E, Wang L, Maghazachi AA (2003). „Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization.”. Eur. J. Immunol.. 33 (8): 2083—9. PMID 12884281. doi:10.1002/eji.200323711.
Xing Y, Ganji SH, Noh JW, Kamanna VS (2005). „Cell density-dependent expression of EDG family receptors and mesangial cell proliferation: role in lysophosphatidic acid-mediated cell growth.”. Am. J. Physiol. Renal Physiol.. 287 (6): F1250—7. PMID 15292052. doi:10.1152/ajprenal.00342.2003.
Gerhard, D. S.; Wagner, L.; Feingold, E. A.; et al. (2004). „The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”. Genome Res.. 14 (10B): 2121—7. PMC 528928 . PMID 15489334. doi:10.1101/gr.2596504.

Vidi još

Receptor lizofosfatidne kiseline

Spoljašnje veze

„Lysophospholipid Receptors: LPA₃”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Архивирано из оригинала 03. 03. 2016. г..

[entrez-1] а ^б „Entrez Gene: LPAR3 Lysophosphatidic acid receptor 3”.

[pmid10488122-2] Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K (1999). „Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid”. J. Biol. Chem.. 274 (39): 27776—85. PMID 10488122. doi:10.1074/jbc.274.39.27776.

[Choi_2010-3] Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J (2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology. 50 (1): 157—186. PMID 20055701. doi:10.1146/annurev.pharmtox.010909.105753.

[1]

[2]

[3]

LPAR3

Funkcija

Reference

Literatura

Vidi još

Spoljašnje veze

Content Disclaimer